The Technical Analyst
ANI Pharmaceuticals Inc [ANIP]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
ANI Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.79% $66.14
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 387.64 mill |
| EPS: | 0.850 |
| P/E: | 77.81 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 20.98 mill |
| Avg Daily Volume: | 0.145 mill |
| RATING 2024-04-23 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 77.81 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.63x |
| Company: PE 77.81 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-52.59 (-179.52%) $-118.73 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 64.36 - 67.76 ( +/- 2.57%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Shanmugam Muthusamy | Sell | 10 423 | Common Stock |
| 2024-04-19 | Shanmugam Muthusamy | Sell | 16 809 | Common Stock |
| 2024-04-15 | Shanmugam Muthusamy | Sell | 7 414 | Common Stock |
| 2024-04-16 | Shanmugam Muthusamy | Sell | 5 834 | Common Stock |
| 2024-04-17 | Shanmugam Muthusamy | Sell | 9 520 | Common Stock |
| INSIDER POWER |
|---|
| -32.47 |
| Last 100 transactions |
| Buy: 351 092 | Sell: 732 643 |
Forecast:
16:00 - $66.14
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $66.14
Forecast 2: 16:00 - $66.14
Forecast 3: 16:00 - $66.14
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $66.14 (0.79% ) |
| Volume | 0.0850 mill |
| Avg. Vol. | 0.145 mill |
| % of Avg. Vol | 58.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ANIP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:30 | sell | $55.72 | N/A | Active |
|---|
ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Latest Press Releases
2024-04-18 16:05:00 - Press Release
Ani Pharmaceuticals To Discuss First Quarter 2024 Financial Results On May 10, 2024, At 8:30 A.m. Et
Baudette, minn., april 18, 2024 (globe newswire) -- ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced that the company will release its first quarter 2024 financial results on friday, may 10, 2024, prior to the market open.
2024-04-09 06:50:00 - Press Release
Ani Pharmaceuticals Announces The Launch Of Baclofen Oral Suspension
Baudette, minn., april 09, 2024 (globe newswire) -- ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced the launch of baclofen oral suspension, a generic version of the reference listed drug (rld) fleqsuvy®.
2024-04-04 06:50:00 - Press Release
Ani Pharmaceuticals Recognizes Sarcoidosis Awareness Month And Patients Living With Sarcoidosis
--ani pharmaceuticals is proud to support sarcoidosis disease awareness-- --ani pharmaceuticals is proud to support sarcoidosis disease awareness--
2024-04-03 06:50:00 - Press Release
Ani Pharmaceuticals To Participate At The Piper Sandler Spring Biopharma Symposium
Baudette, minn., april 03, 2024 (globe newswire) -- ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced that nikhil lalwani, chief executive officer, and stephen carey, chief financial officer, will host investor meetings at the piper sandler spring biopharma symposium on wednesday, april 17, 2024, at the encore boston harbor.
2024-03-27 06:50:00 - Press Release
Ani Pharmaceuticals Announces The Launch Of Levofloxacin Oral Solution, Usp
Baudette, minn., march 27, 2024 (globe newswire) -- ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced the launch of levofloxacin oral solution, a generic version of the reference listed drug (rld) levaquin®. the current annual u.s. market for levofloxacin oral solution is approximately $7.1 million, according to latest estimates from iqvia/ims health, a leading healthcare data and analytics provider.
Latest News
2024-04-18 16:05:00 - GlobeNewsWire
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.
2024-04-15 13:15:38 - Zacks Investment Research
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2024-04-05 10:35:24 - Zacks Investment Research
Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
2024-03-27 19:21:11 - Zacks Investment Research
ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing
ANI Pharmaceuticals (ANIP) concluded the recent trading session at $69.69, signifying a +0.2% move from its prior day's close.
2024-03-26 10:16:03 - Zacks Investment Research
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
2024-03-20 10:36:15 - Zacks Investment Research
ANI (ANIP) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
2024-03-14 10:46:33 - Zacks Investment Research
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
2024-03-12 05:00:00 - Seeking Alpha
Top 10 Small-Cap Stocks (SA Quant)
The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small-Cap index (~+15%). Small-cap stocks present enticing prospects for growth and value for investors willing to capitalize on calculated risks. The S&P 500 P/E is 25x vs. the S&P Small-Cap at 14.8x.
2024-03-06 13:01:20 - Zacks Investment Research
What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now?
Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-03-01 10:31:09 - Zacks Investment Research
Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?